Rhumbline Advisers boosted its holdings in shares of Natus Medical Incorporated (NASDAQ:NTUS) by 1.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,532 shares of the company’s stock after buying an additional 1,585 shares during the period. Rhumbline Advisers owned approximately 0.34% of Natus Medical worth $3,010,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also made changes to their positions in the stock. Squarepoint Ops LLC increased its position in Natus Medical by 5.2% during the 4th quarter. Squarepoint Ops LLC now owns 12,535 shares of the company’s stock valued at $251,000 after buying an additional 624 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Natus Medical by 5.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 20,626 shares of the company’s stock valued at $413,000 after buying an additional 977 shares in the last quarter. Keybank National Association OH increased its position in Natus Medical by 4.4% during the 4th quarter. Keybank National Association OH now owns 25,550 shares of the company’s stock valued at $512,000 after buying an additional 1,075 shares in the last quarter. Royce & Associates LP increased its position in Natus Medical by 1.3% during the 4th quarter. Royce & Associates LP now owns 106,095 shares of the company’s stock valued at $2,126,000 after buying an additional 1,335 shares in the last quarter. Finally, Veriti Management LLC acquired a new position in Natus Medical during the 4th quarter valued at about $40,000. 95.76% of the stock is currently owned by institutional investors.
In other news, VP Dong Chune Christopher Chung sold 10,108 shares of the company’s stock in a transaction dated Wednesday, May 12th. The stock was sold at an average price of $27.47, for a total value of $277,666.76. Following the sale, the vice president now owns 161,345 shares in the company, valued at $4,432,147.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 67,196 shares of company stock worth $1,855,398 in the last 90 days. Company insiders own 1.50% of the company’s stock.
Natus Medical (NASDAQ:NTUS) last posted its quarterly earnings results on Thursday, May 6th. The company reported $0.16 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The business had revenue of $114.93 million for the quarter, compared to the consensus estimate of $111.40 million. Natus Medical had a positive return on equity of 4.28% and a negative net margin of 2.52%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.04 EPS. As a group, research analysts predict that Natus Medical Incorporated will post 1.19 earnings per share for the current fiscal year.
Separately, Zacks Investment Research downgraded Natus Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 29th.
About Natus Medical
Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.
Featured Article: What is a capital gains distribution?
Want to see what other hedge funds are holding NTUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:NTUS).
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.